I'm not going to finish tonight.
I'm trying to prepare a well balanced presentation (still extremely shallow) on the current state of AD pharmacology. Thus I'm trying to digest trends in cholinesterase inhibitors (galantamin, donepezil [Aricept], tetrahydroaminoacridine [Tacrine], rivastigmine, metrifonate ++), amyloid (APP/Aß42) inhibitors (direct?? - AIT-082 [Neotrofin], anti-ß-and anti-g secretases, anti-Aß42 vaccine [Betabloc/AN-1792 ++] ; indirect?? - antioxidants, NSAIDs, estrogen, etc), uncompetitive N-methyl-D-aspartate (NMDA) antagonists (Memantine)......to name a few.
I'll do my best to consolidate this and present my viewpoint as soon as possible. |
